“调神针刺法”治疗过敏性鼻炎的临床疗效观察
|
摘要
过敏性鼻炎(Allergic Rhinits, AR)发病率高,社会问题严重。保守估计,全世界的过敏性鼻炎患者在5亿左右,且患病人数在逐渐升高。每年,在AR治疗上的直接和间接投入巨大。研究证实,过敏性鼻炎的发病与情志的异常变化有关,也会导致患者精神状况的明显下降。本研究在传统针灸治疗过敏性鼻炎方法的基础上,针对情志变化的病因病机,加用“调神”之穴并采用了电针刺激,从而加强了针刺“调神”的作用,进一步优化治疗方案。通过观察此方法的临床疗效及其对生活质量的影响,并初步探讨其作用机制。
目的观察“调神针刺法”治疗持续性过敏性鼻炎的临床疗效,以及该方法对于患者生活质量的影响,并且初步探讨本方法的作用机制,为针刺治疗过敏性鼻炎提供针灸治疗思路。
方法
分组：将符合纳入标准的持续性中重度过敏性鼻炎患者共60例,采用严格随机对照试验的方法,将患者分为治疗组(针刺组)和对照组(药物组)各30例。
干预措施
1治疗组选穴：迎香、印堂、合谷、肺俞、脾俞、肾俞、肝俞、大椎、百会、太冲。操作：先取俯卧位,针刺大椎、肺俞、脾俞、肝俞、肾俞,诸穴得气后,各施予捻转补法30秒出针。再取仰卧位,针刺其余腧穴,诸穴得气后,施予平补平泻手法30秒。印堂穴与百会穴、双侧迎香穴分别接电针仪,选择疏密波,频率为2/15HZ,强度以患者耐受为度,留针20分钟。治疗组隔日针刺1次,每周针刺3次。连续治疗四周,共针刺12次。
2对照组：口服西替利嗪,每日一次,每次10mg,连续服用四周。
观察指标
1主要观察指标：鼻症状总分(TNSS)评价症状变化情况。
2次要观察指标：鼻伴随症状总分(TNNSS)辅助评价症状变化情况,鼻结膜炎相关生命质量调查问卷(RQLQ)评价对患者生活质量的影响。
3实验室指标：嗜酸粒细胞总数(EOS)和血清总IgE水平初步探讨该方法的临床机制。
结果
1完成情况：共纳入符合入选标准的患者60例,完成试验55例,其中治疗组27例,对照组28例,脱落5例。
2鼻症状总分(TNSS)治疗前后比较(主要疗效评价指标)
经过4周治疗后,治疗组与对照组组内比较,治疗前后TNSS评分的差异具有统计学意义(P<0.05)；而经过治疗2周后,治疗组与对照组的组间TNSS评分的差异具有统计学意义(P<0.05),治疗4周后,治疗组与对照组的组间TNSS评分的差异无统计学意义(P>0.05)。结果表明,无论经过针刺治疗还是药物治疗,TNSS症状评分均较治疗前下降,提示两种方法均可改善过敏性鼻炎患者的临床症状；治疗2周后,药物治疗效果优于针刺治疗,但是经过4周的治疗后,两种方法疗效相同。
3鼻伴随症状评分(TNNSS)和鼻结膜炎生活质量问卷调查(RQLQ)治疗前后比较(次要疗效评价指标)
鼻伴随症状评分(TNNSS):经治疗4周后,治疗组与对照组组内比较,疗前与疗后TNNSS评分差异均具有统计学意义(P<0.01)；经过治疗2周后,治疗组与对照组的组间TNNSS评分的差异具有统计学意义(P<0.05),治疗4周后,治疗组与对照组的组间TNNSS评分的差异无统计学意义(P>0.05)。结果表明,无论经过针刺治疗还是药物治疗,TNNSS症状评分均较治疗前下降,提示两种方法均可改善过敏性鼻炎患者的鼻部伴随症状；治疗2周后,药物治疗效果优于针刺治疗,但是经过4周的治疗后,两种方法疗效相同。
RQLQ评分：经过治疗4周后,治疗组与对照组组内比较,疗前与疗后评分差异均具有统计学意义(P<0.05)；同时,治疗组与对照组疗前与疗后关于睡眠问题的评分差异均具有统计学意义(P<0.05)。患者在治疗2周及4周后,治疗组与对照组组间对比,RQLQ评分差异有统计学意义(P<0.05)；经治疗4周后,两组患者由过敏性鼻炎引起的睡眠问题评分的差异无统计学意义(P>0.05)。结果提示,经过4周治疗,针刺治疗与药物治疗均可以使患者的生活质量及睡眠问题得到明显改善,药物治疗对于患者生活质量的改善优于针刺治疗;但是,针刺治疗对于患者睡眠问题的改善取得了与药物治疗相同的效果。
4实验室指标(EOS与IgE)
经过4周治疗后,治疗组与对照组的嗜酸粒细胞计数(EOS)的差异无统计学意义(P>0.05),两组的IgE水平的差异具有统计学的意义(P<0.05);而经治疗4周后,两组间IgE水平的差异无统计学意义(P>0.05)。结果提示,经过4周治疗后,针刺与药物治疗均可以使患者IgE水平显著下降,且疗效相同;但是,对于患者EOS无明显影响。
5安全性指标：在试验过程中,治疗组出现1例患者合谷穴处皮下瘀血情况,未再针刺此穴位,约3天后瘀血吸收,该例患者完成了接下来的全部试验。对照组无不良反应报告。
结论：应用“调神针刺法”治疗持续性中重度过敏性鼻炎,可以改善患者鼻炎症状,以及鼻炎伴随症状,提高患者生活质量,尤其是改善因鼻炎引起的睡眠问题,同时可以降低患者的血清总IgE水平。此方法安全性好,无严重不良反应。
Allergic rhinitis, is high incidence disease which causes serious social problem. A conservative estimate, these are more than500million patients with allergic rhinitis in the world, and the number of cases increased. In addition to the symptoms of nasal itself, studies confirm that the onset of allergic rhinitis is associated with psychological disorders. Each year, the direct and indirect investment in the treatment of AR is enormous. Modern medicine has established the standard treatment for the disease, such as avoid to contact allergen, drugs and immune therapy, surgery, etc. In effective treatment at the same time, however, there is obviously difficult to avoid adverse reactions. Large clinical studies confirmed that acupuncture and moxibustion treatment of AR is effective, no side effects, and not easy to produce resistance, high dependence of patients receiving treatment. In traditional acupuncture methods, on the basis of regulating, electro acupuncture is adopted, which strengthens the role of regulating-acupuncture, to further optimize the treatment plan. This study intends to observe the clinical curative effect of this method and its influence on quality of life, and explore its mechanism.
Objective:To observe the clinical efficacy of "Regulating-acupuncture" for the treatment of persistent allergic rhinitis, as well as impact for the quality of life. Try to provide the better clinical treatment of acupuncture for allergic rhinitis.
Methods:persistent moderate to severe allergic rhinitis patients who met the inclusion criteria, using rigorous randomized controlled trials, were divided into a treatment group and a control group. The two groups of patients with different interventions, which is lasting for4weeks. The points of the treatment group:Yingxiang (GV29), YinTang (LI20), Hegu(L14), Feishu (BL13), pishu(BL20), Shenshu (BL23), ganshu(BL18), dazhui (GV14), Baihui (GV20), Taichong(LR3). First, taking the prone position, to bring about the desired sensation of Feishu (BL13), pishu (BL20), Shenshu (BL23), ganshu(BL18), dazhui (GV14),and each administered twirling of needle for30seconds. Supine position, acupuncture the rest of the acupoints, bringing about the desired sensation of these points and nourishing flat purging gimmick for30seconds. Using electro-acupuncture for Yintang, Baihui and bilateral Ying Xiang points respectively, then the select the dilatational wave, the frequency2/15HZ, strengthen to the degree of patient tolerance,20minutes. The treatment group takes the therapy every other day, three times per week. Continuous treatment, acupuncture12times. The control group was treated with cetirizine,10mg once a day, taking four weeks. Compare two groups of patients' TNSS, TNNSS and RQLQ before and after treatment, as well as the total number of eosinophils(EOS) and serum total IgE level, clinical efficacy for the treatment of persistent allergic rhinitis on the regulating-acupuncture Law, and to evaluate the impact on quality of life, the safety evaluation of the treatment of allergic rhinitis and the regulating-acupuncture Law.
Results:
1Completion:A total of60patients met the inclusion criteria,55cases completed the trial, in which27cases in the treatment group,28cases in the control group, Shedding five cases.
2Primary efficacy evaluation:After acupuncture treatment or medication, both TNSS were decreased. After statistical analysis, the treatment group and the control group before treatment and after treatment TNSS score differences were statistically significant (P<0.05). The nasal symptoms arc improved after4weeks treatment of two interventions that TNSS score lower than before. In2weeks after treatment, patients in treatment group and control group of TNSS score difference was statistically significant (P<0.05); After treatment ends (4weeks), the treatment group and control group of TNSS score there was no statistically significant difference.
3Secondary efficacy evaluation:
TNNSS:Treatment group and control group before treatment and after treatment TNNSS score differences were statistically significant (P<0.01). TNNSS score is lower than before treatment, after treatment the tip4weeks after treatment, respectively, in patients with nasal symptom scores decline. Treatment and control groups after two weeks of treatment, the difference was statistically significant (P<0.05).4weeks after treatment, the treatment group and control group of TNNSS score there was no statistically significant difference (P>0.05), but the grading fall into the group, after treatment, the symptoms were improved in both groups.
RQLQ Rating:the two groups RQLQ ratings have decreased. After statistical analysis, the differences in scores before and after treatment in the treatment group and the control group treatment were statistically significant (P<0.05). Score below baseline values, after treatment and four weeks after the prompt application of two interventions related quality of life of patients with nasal symptoms improved. Sleep problem scores of the two groups were decreased. After statistical analysis, the treatment and control groups before treatment and after treatment differences in scores on the sleep problems was statistically significant (P<0.05). Score below baseline values before treatment, after treatment and four weeks after the prompt application of two interventions, patients with symptoms of allergic rhinitis-related sleep problems were improved. After two weeks and four weeks of treatment, the patients, the treatment group and the control group RQLQ score difference was statistically significant (P<0.05). After4weeks of treatment, the two groups of patients with allergic rhinitis caused sleep problems score was no significant difference (P>0.05). Prompted two groups of patients were treated the same degree of improvement of sleep problems.
Laboratory parameters (EOS with IgE):before and after the treatment, the treatment group and the control group, the eosinophil count (EOS) difference was not statistically significant (P>0.05), the IgE differences with statistical significance (P<0.05). IgE levels after treatment than before treatment decreased, and the difference was not statistically significant (P>0.05) between the two groups IgE levels.
Security indicators:Appeared in the process of test, the treatment group1patients li4point of subcutaneous blood stasis, not acupuncture the points again, about3days after the blood stasis absorption, all the patients completed the next test. Control group has no adverse reaction report.
Conclusion:the regulating-acupunture treatment of persistent moderate to severe allergic rhinitis, can improve the symptoms of patients with rhinitis (TNSS), as well as the rhinitis associated symptoms (TNNSS), to improve the quality of life in patients with RQLQ, especially due to rhinitis caused sleep problems; reduce patient serum total IgE. This method is good security, no serious adverse reactions.
目的观察“调神针刺法”治疗持续性过敏性鼻炎的临床疗效,以及该方法对于患者生活质量的影响,并且初步探讨本方法的作用机制,为针刺治疗过敏性鼻炎提供针灸治疗思路。
方法
分组：将符合纳入标准的持续性中重度过敏性鼻炎患者共60例,采用严格随机对照试验的方法,将患者分为治疗组(针刺组)和对照组(药物组)各30例。
干预措施
1治疗组选穴：迎香、印堂、合谷、肺俞、脾俞、肾俞、肝俞、大椎、百会、太冲。操作：先取俯卧位,针刺大椎、肺俞、脾俞、肝俞、肾俞,诸穴得气后,各施予捻转补法30秒出针。再取仰卧位,针刺其余腧穴,诸穴得气后,施予平补平泻手法30秒。印堂穴与百会穴、双侧迎香穴分别接电针仪,选择疏密波,频率为2/15HZ,强度以患者耐受为度,留针20分钟。治疗组隔日针刺1次,每周针刺3次。连续治疗四周,共针刺12次。
2对照组：口服西替利嗪,每日一次,每次10mg,连续服用四周。
观察指标
1主要观察指标：鼻症状总分(TNSS)评价症状变化情况。
2次要观察指标：鼻伴随症状总分(TNNSS)辅助评价症状变化情况,鼻结膜炎相关生命质量调查问卷(RQLQ)评价对患者生活质量的影响。
3实验室指标：嗜酸粒细胞总数(EOS)和血清总IgE水平初步探讨该方法的临床机制。
结果
1完成情况：共纳入符合入选标准的患者60例,完成试验55例,其中治疗组27例,对照组28例,脱落5例。
2鼻症状总分(TNSS)治疗前后比较(主要疗效评价指标)
经过4周治疗后,治疗组与对照组组内比较,治疗前后TNSS评分的差异具有统计学意义(P<0.05)；而经过治疗2周后,治疗组与对照组的组间TNSS评分的差异具有统计学意义(P<0.05),治疗4周后,治疗组与对照组的组间TNSS评分的差异无统计学意义(P>0.05)。结果表明,无论经过针刺治疗还是药物治疗,TNSS症状评分均较治疗前下降,提示两种方法均可改善过敏性鼻炎患者的临床症状；治疗2周后,药物治疗效果优于针刺治疗,但是经过4周的治疗后,两种方法疗效相同。
3鼻伴随症状评分(TNNSS)和鼻结膜炎生活质量问卷调查(RQLQ)治疗前后比较(次要疗效评价指标)
鼻伴随症状评分(TNNSS):经治疗4周后,治疗组与对照组组内比较,疗前与疗后TNNSS评分差异均具有统计学意义(P<0.01)；经过治疗2周后,治疗组与对照组的组间TNNSS评分的差异具有统计学意义(P<0.05),治疗4周后,治疗组与对照组的组间TNNSS评分的差异无统计学意义(P>0.05)。结果表明,无论经过针刺治疗还是药物治疗,TNNSS症状评分均较治疗前下降,提示两种方法均可改善过敏性鼻炎患者的鼻部伴随症状；治疗2周后,药物治疗效果优于针刺治疗,但是经过4周的治疗后,两种方法疗效相同。
RQLQ评分：经过治疗4周后,治疗组与对照组组内比较,疗前与疗后评分差异均具有统计学意义(P<0.05)；同时,治疗组与对照组疗前与疗后关于睡眠问题的评分差异均具有统计学意义(P<0.05)。患者在治疗2周及4周后,治疗组与对照组组间对比,RQLQ评分差异有统计学意义(P<0.05)；经治疗4周后,两组患者由过敏性鼻炎引起的睡眠问题评分的差异无统计学意义(P>0.05)。结果提示,经过4周治疗,针刺治疗与药物治疗均可以使患者的生活质量及睡眠问题得到明显改善,药物治疗对于患者生活质量的改善优于针刺治疗;但是,针刺治疗对于患者睡眠问题的改善取得了与药物治疗相同的效果。
4实验室指标(EOS与IgE)
经过4周治疗后,治疗组与对照组的嗜酸粒细胞计数(EOS)的差异无统计学意义(P>0.05),两组的IgE水平的差异具有统计学的意义(P<0.05);而经治疗4周后,两组间IgE水平的差异无统计学意义(P>0.05)。结果提示,经过4周治疗后,针刺与药物治疗均可以使患者IgE水平显著下降,且疗效相同;但是,对于患者EOS无明显影响。
5安全性指标：在试验过程中,治疗组出现1例患者合谷穴处皮下瘀血情况,未再针刺此穴位,约3天后瘀血吸收,该例患者完成了接下来的全部试验。对照组无不良反应报告。
结论：应用“调神针刺法”治疗持续性中重度过敏性鼻炎,可以改善患者鼻炎症状,以及鼻炎伴随症状,提高患者生活质量,尤其是改善因鼻炎引起的睡眠问题,同时可以降低患者的血清总IgE水平。此方法安全性好,无严重不良反应。
Allergic rhinitis, is high incidence disease which causes serious social problem. A conservative estimate, these are more than500million patients with allergic rhinitis in the world, and the number of cases increased. In addition to the symptoms of nasal itself, studies confirm that the onset of allergic rhinitis is associated with psychological disorders. Each year, the direct and indirect investment in the treatment of AR is enormous. Modern medicine has established the standard treatment for the disease, such as avoid to contact allergen, drugs and immune therapy, surgery, etc. In effective treatment at the same time, however, there is obviously difficult to avoid adverse reactions. Large clinical studies confirmed that acupuncture and moxibustion treatment of AR is effective, no side effects, and not easy to produce resistance, high dependence of patients receiving treatment. In traditional acupuncture methods, on the basis of regulating, electro acupuncture is adopted, which strengthens the role of regulating-acupuncture, to further optimize the treatment plan. This study intends to observe the clinical curative effect of this method and its influence on quality of life, and explore its mechanism.
Objective:To observe the clinical efficacy of "Regulating-acupuncture" for the treatment of persistent allergic rhinitis, as well as impact for the quality of life. Try to provide the better clinical treatment of acupuncture for allergic rhinitis.
Methods:persistent moderate to severe allergic rhinitis patients who met the inclusion criteria, using rigorous randomized controlled trials, were divided into a treatment group and a control group. The two groups of patients with different interventions, which is lasting for4weeks. The points of the treatment group:Yingxiang (GV29), YinTang (LI20), Hegu(L14), Feishu (BL13), pishu(BL20), Shenshu (BL23), ganshu(BL18), dazhui (GV14), Baihui (GV20), Taichong(LR3). First, taking the prone position, to bring about the desired sensation of Feishu (BL13), pishu (BL20), Shenshu (BL23), ganshu(BL18), dazhui (GV14),and each administered twirling of needle for30seconds. Supine position, acupuncture the rest of the acupoints, bringing about the desired sensation of these points and nourishing flat purging gimmick for30seconds. Using electro-acupuncture for Yintang, Baihui and bilateral Ying Xiang points respectively, then the select the dilatational wave, the frequency2/15HZ, strengthen to the degree of patient tolerance,20minutes. The treatment group takes the therapy every other day, three times per week. Continuous treatment, acupuncture12times. The control group was treated with cetirizine,10mg once a day, taking four weeks. Compare two groups of patients' TNSS, TNNSS and RQLQ before and after treatment, as well as the total number of eosinophils(EOS) and serum total IgE level, clinical efficacy for the treatment of persistent allergic rhinitis on the regulating-acupuncture Law, and to evaluate the impact on quality of life, the safety evaluation of the treatment of allergic rhinitis and the regulating-acupuncture Law.
Results:
1Completion:A total of60patients met the inclusion criteria,55cases completed the trial, in which27cases in the treatment group,28cases in the control group, Shedding five cases.
2Primary efficacy evaluation:After acupuncture treatment or medication, both TNSS were decreased. After statistical analysis, the treatment group and the control group before treatment and after treatment TNSS score differences were statistically significant (P<0.05). The nasal symptoms arc improved after4weeks treatment of two interventions that TNSS score lower than before. In2weeks after treatment, patients in treatment group and control group of TNSS score difference was statistically significant (P<0.05); After treatment ends (4weeks), the treatment group and control group of TNSS score there was no statistically significant difference.
3Secondary efficacy evaluation:
TNNSS:Treatment group and control group before treatment and after treatment TNNSS score differences were statistically significant (P<0.01). TNNSS score is lower than before treatment, after treatment the tip4weeks after treatment, respectively, in patients with nasal symptom scores decline. Treatment and control groups after two weeks of treatment, the difference was statistically significant (P<0.05).4weeks after treatment, the treatment group and control group of TNNSS score there was no statistically significant difference (P>0.05), but the grading fall into the group, after treatment, the symptoms were improved in both groups.
RQLQ Rating:the two groups RQLQ ratings have decreased. After statistical analysis, the differences in scores before and after treatment in the treatment group and the control group treatment were statistically significant (P<0.05). Score below baseline values, after treatment and four weeks after the prompt application of two interventions related quality of life of patients with nasal symptoms improved. Sleep problem scores of the two groups were decreased. After statistical analysis, the treatment and control groups before treatment and after treatment differences in scores on the sleep problems was statistically significant (P<0.05). Score below baseline values before treatment, after treatment and four weeks after the prompt application of two interventions, patients with symptoms of allergic rhinitis-related sleep problems were improved. After two weeks and four weeks of treatment, the patients, the treatment group and the control group RQLQ score difference was statistically significant (P<0.05). After4weeks of treatment, the two groups of patients with allergic rhinitis caused sleep problems score was no significant difference (P>0.05). Prompted two groups of patients were treated the same degree of improvement of sleep problems.
Laboratory parameters (EOS with IgE):before and after the treatment, the treatment group and the control group, the eosinophil count (EOS) difference was not statistically significant (P>0.05), the IgE differences with statistical significance (P<0.05). IgE levels after treatment than before treatment decreased, and the difference was not statistically significant (P>0.05) between the two groups IgE levels.
Security indicators:Appeared in the process of test, the treatment group1patients li4point of subcutaneous blood stasis, not acupuncture the points again, about3days after the blood stasis absorption, all the patients completed the next test. Control group has no adverse reaction report.
Conclusion:the regulating-acupunture treatment of persistent moderate to severe allergic rhinitis, can improve the symptoms of patients with rhinitis (TNSS), as well as the rhinitis associated symptoms (TNNSS), to improve the quality of life in patients with RQLQ, especially due to rhinitis caused sleep problems; reduce patient serum total IgE. This method is good security, no serious adverse reactions.
引文
[1]彭尧书,杨惊宇.鼻三针配火罐治疗慢性过敏性鼻炎67例[J].现代中医药,2006,26(4) ： 59
[2]倪爱民.针刺治疗过敏性鼻炎与药物治疗对比观察[J].上海针灸杂志,2006,25(11)：16-17
[3]刘彩梅.针刺蝶腭神经节治疗鼻渊76例[J].现代中医药,2009,29；No.17006：51.
[4]王凤玲,许振林.针刺配合颧骼穴位注射治疗过敏性鼻炎疗效观察[J].职业与健康,2009,2517：1889-1890.
[5]王胜.深刺下关穴为主治疗过敏性鼻炎[J].针灸临床杂志,2010,2604：45-46.
[6]刘业帅,陈戈. “鼻三针”结合超短波治疗过敏性鼻炎的疗效观察[J].甘肃中医,2010,2308：31-32.
[7]桑莉.针刺治疗过敏性鼻炎45例分析[J].慢性病学杂志,2010,1201：58.
[8]陈仲新.针刺治疗过敏性鼻炎疗效观察[J].中国针灸,2007,27(8)：578-580.
[9]姚学英.针刺加艾灸治疗过敏性鼻炎60例[J].上海针灸杂志,2007,26(2)：14
[10]程艳红.头部电针透穴疗法治疗过敏性鼻炎45例[J].首都医药,2010,17(22)：45.
[11]李兰,白杨,陈新.针刺治疗过敏性鼻炎临床研究[J].辽宁中医杂志,2009,36(9)：1565-1566
[12]赵树波,宁金梅,刘德华,杨明早.针刺联合依巴斯汀治疗过敏性鼻炎的疗效观察[J].航空航天医学杂志,2012,23(10)：1248-1249.
[13]何天有,李惠琴,赵耀东.透刺为主治疗过敏性鼻炎60例[J].中国针灸,2006,26(2)：110-112.
[14]杨白燕.针刺治疗过敏性鼻炎62例临床观察[J].天津中医药,2008,25(1)：74.
[15]郑永生.针刺治疗花粉病[J].中国中医药现代远程教育,2011,9(3)：57.
[16]林艳霞,范丽英.针灸治疗急性发作期过敏性鼻炎的临床观察[J].海南医学院学报,2011,17(4)：508-510.
[17]罗雪梅,王建中.针刺穴位治疗过敏性鼻炎的疗效分析[J].中国临床医学,2012,(05)：553-554.
[18]王军,陈晟,谭程,赵吉平.灸法治疗常见过敏性疾病作用机制及临床应用探讨[J].临床误诊误治,2012,(03)：105-108.
[19]夏筱方.针刺加灸治疗过敏性鼻炎56例[J].甘肃中医,2006,11：35.
[20]陈振虎,江钢辉,王培源.针刺结合艾灸治疗过敏性鼻炎42例[J].四川中医,2005,09：102-103.
[21]胡志平,李小军,黄克伟,等.隔附子饼灸治疗过敏性鼻炎82例[J].上海针灸杂志,2005,22(5)：61.
[22]廉南,赵岚,雷中杰.针刺结合脐灸法治疗儿童过敏性鼻炎临床观察.成都中医药大学学报,20002,25(4)：12-13.
[23]张舒雁,杨金发,马泽云,等.三伏天穴位贴敷加卡介苗穴位注射防治变应性鼻炎50例观察[J].浙江中医杂志,2006,41(8)：475.
[24]姬晓兰,宋晓平.单用斑蝥天灸治疗过敏性鼻炎的临床研究.新疆中医药,2006,24(4)：42-44.
[25]李国徽,胡雨华,陈凌,等.三伏天灸治疗变应性鼻炎600例[J].陕西中医,20009,30(7)：885.
[26]王权全,陈海林,黄慧敏,等.穴位注射结合推拿治疗常年性过敏性鼻炎临床研究[J].中医学报,2012,27(2)：247.
[27]杨洋,吴乃桐.穴位注射配合自拟补肾脱敏汤治疗过敏性鼻炎71例[J].云南中医中药杂志,2010,31(5)：56.
[28]于力,高启孝.穴位注射治疗过敏性鼻炎的疗效观察.宁夏医学杂志,2006,28(4)：307-308.
[29]贺守阳.穴位埋线治疗过敏性鼻炎50例.针灸临床杂志,1997,13(Z1)：60-61.
[30]杜艳,吴海标,何邦广,等.背俞穴埋线治疗变应性鼻炎64例临床观察[J].河南中医,2009,29(4)：391.
[31]Er W,von Mutius E. Hygiene hypothesis and cndotoxin:what is the evidence?. Curr Opin Allergy Clin Immunol,2004,4 (2):113-117.
[32]Kim JI, Lee MS, Jung SY, et al. Acupuncture for persistent allergic rhinitis: a multi-centre, randomised, controlled trial protocol. Trials,2009 (10):54.
[33]Jan L, Bousquet J,Carlos E, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines:2010 Revision. J Allergy Clin Immunol,2010,126(3):466-476.
[34]Roberts J,Huissoon A, Dretzke J,et al.A systematic review of the clinical effectiveness of acupuncture for allergic rhinitis. BMC Complement Altcrn Med, 2008:8-13.
[35]Lee MS, Pittler MH, Shin BC,et al. Acupuncture for allergic rhinitis:a systematic review. Ann Allergy Asthma Immunol,2009(102):269-279.
[36]刘慧林,刘雪梅,史宗道.针刺临床对照试验中干预措施报告的标准：STRICTA(建议).中国循证医学杂志,2003,3(3)：235-237.
[37]费宇彤,刘建平.针刺临床试验中有关治疗措施的报告-STRICTA标准介绍及评价.中医杂志,2007,48(11)：983-985.
[38]Roberts, J., Huissoon, A., Dretzke, J.,Wang, D., Hyde, C.,2008. A systematic review of theclinical effectiveness of acupuncture for allergic rhinitis. BMC Complement. Altern. Med.8-13.
[39]Williamson, L., Yudkin, P., Livingston, R., Prasad, K., Fuller, A., Lawrence, M.,1996. Hay fever treatment in general practice:a randomised controlled trial comparing standardised western acupuncture with sham acupuncture. Acupunct. Med.14,6-10.
[40]Magnusson, A. L., Svcnsson, R. E., Leirvik, C., Gunnarsson, R. K.,2004. The effect ofacupuncturc on allergic rhinitis:a randomized controlled clinical trial. Am. J. Chin. Med.32,105-115.
[41]Xue, C.C., English, R., Zhang, J. J., Da Costa, C., Li, G.,2002. Effect of acupuncture in the treatment of seasonal allergic rhinitis:a randomized controlled clinical trial. Am. J.Chin. Med.30,1-11.
[42]Ng, D. K., Chow, P. Y., Ming, S. P., Hong, S. H., Lau, S., Tse, D., Kwong, W. K., Wong, M. F.,Wong, W. H., Fu, Y. M., Kwok, K. L., Li, H., Ho, J. C.,2004. A double- blind, randomized, placebo-controlled trial of acupuncture for the treatment of childhood persistent allergic rhinitis. Pediatrics 114,1242-1247.
[43]Wolkenstein E, Horak E. Protective effect of acupuncture in confrontation with rhinitis caused by allergen provocation. Wien Med Wschr.1998; 148:450-453.
[44]谭程,王朋,王军,王鹏,白鹏,张佳佳,石志红,赵吉平.过敏性鼻炎的针灸辨证论治思路[J].临床误诊误治,2012,(03)：102-105.
[1]Dykewicz MS, Fineman S, Skoner DP. Joint task force summary statements on diagnosis and management of rhinitis. Ann Allergy Asthma Immunol,1998;81 1240 (5 pt 2):474-7.
[2]international consensus report on diagnosis, management of rhinitis. International Rhinitis Management Working Group. Allergy 1994; 49 (suppl 19):1-34.
[3]Douglass JA, O'Hehir RE. Diagnosis, treatment and prevention of allergic disease:the basics. Med J Aust 2006;185 (4):228-33.
[4]Droste JH,Kerhof M,deMonchy JG,et al.Association of skin test reactivity, specific IgE, total IgE, and eosinophils with nasal symptoms in a community-based population study. The Dutch ECRHS Group. J Allergy Clin Immunol 1996; 97(4):922-32.
[5]Agency for Healthcare Research and Quality. Management of allergic and nonallergic rhinitis. Evidence report/technology assessment No.54, Publication No.1245 02-E024,May2002. Rockville, Md:Agency for Healthcare Research and Quality;
[6]Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811.
[7]Lambrecht BN. Allergen uptake and presentation by dendritic cells. Curr Opin Allergy Clin Immunol 2001; 1 (1):51-9.
[8]Takhar P, Smurthwaite L, Coker HA, et al. Allergen drives class switching to IgE in the nasal mucosa in allergic rhinitis. J Immunol 2005; 174(8):5024-32.
[9]Min YG. The pathophysiology, diagnosis and treatment of allergic rhinitis. Allergy Asthma Immunol Res 2010;2 (2):65-76.
[10]Willsie SK. Improved strategies and new treatment options for allergic rhinitis. J Am Osteopath Assoc 2002; 102(6 supplement 2):S7-S14.
[11]Brozek JL, Bousquet J, Baena-Cagnani CE,ct al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines:2010 revision. J Allergy Clin Immunol 2010; 126(3):466-76.
[12]Tashiro M, Sakurada Y, Iwabuchi K, ct al. Central effects of fexofenadine and cetirizine:measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. J Clin Pharmacol 2004;44 (8):890-900.
[13]Bousquet J, Van Cauwenberge P, Bachcrt C, ct al. Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI), Allergic Rhinitis and its Impact on Asthma (ARIA). Allergy 2003;58 (3):192-7.
[14]Bussc W, Kraft M. Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. Chest 2005;127 (4):1312-26.
[15]Modgill V, Badyal DK, Verghese A. Efficacy and safety of montelukast add-on therapy in allergic rhinitis. Methods Find Exp Clin Pharmacol 2010; 32(9):669-74
[16]Ramey JT, Bailen E, Lockey RF. Rhinitis medicamentosa. J Investig Allergol Clin Immunol 2006;16 (3):148-55.
[17]Stcnton GR, Chow SM, Lau HY. Inhibition of rat peritoncal mast cell exocytosis by frusemide:a comparison with disodium cromoglycatc. Life Sci 1998; 62 (3):PL49-54.
[18]Senti G, Prinz Vavricka BM, Erdmann I, et al.Intralymphatic allergen administration renders specific immunotherapy faster and safer:a randomized controlled trial. Proc Natl Acad Sci USA 2008;105 (46):8-12.
[19]Chervinsky P, Casale T, Townley R, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2003;91 (2):160-7.
[20]Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106 (2):253-9.
[21]Wright RJ, Cohen RT, Cohen S.The impact of stress on the development and expression of atopy. Curr Opin Allergy Clin Immunol 2005;5 (1):23-9.
[22]Postolache TT, Lapidus M, Sander ER, et al. Changes in allergy symptoms and depression scores are positively correlated in patients with recurrent mood disorders exposed to seasonal peaks in aeroaller-gens. Scientific World Journal 2008;7:1968-77
[23]Timonen M, Jokelainen J, Hakko H, et al. Atopy and depression:results from the Northern Finland 1966 Birth Cohort Study. Mol Psychiatry 2003; 8 (8):738-44.
[24]Postolache TT, Komarow H, Tonelli LH. Allergy:a risk factor for suicide? Curr Treat Options Neurol 2008;10(5):363-76.
[25]Marshall PS,O'Hara C, Steinberg P. Effects of seasonal allergic rhinitis on fatigue levels and mood. Psychosom Med 2002;64 (4):684-91.
[26]Tonelli LH, Stiller J, Rujescu D,et al. Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. Acta Psychiatr Scand 2008; 117(3):198-206.
[27]Mossner R, Daniel S, Schmitt A, et al. Modulation of serotonin transporter function by interleukin-4. Life Sci 2001;68 (8):873-80.
[1]中华耳鼻咽喉头颈外科杂志编辑委员会,中华医学会耳鼻咽喉科分会.变应性鼻炎诊断原则和推荐方案(2004,兰州).中华耳鼻咽喉科杂志,2005,166-167.
[2]Bousquet J, Khal taev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA (2)LEN and AllerGen). Allergy 2008;63 (suppl 86):8-160.
[3]Durham SR. Allergic rhinitis. In:Warrell DA, Cox TM, Firth JD, Benz EJJ, eds. Oxford Textbook of Medicine. Oxford, England:Oxford University Press; 2003:1325-1329.
[4]Gupta R, Sheikh A, Strachan DP, Anderson HR:Time trends in allergic disorders in the UK [J]. Thorax,2007,2:91-96.
[5]Van Cauwenberge P, Bachert C, Passalacqua, G, et al, Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology Allergy [J],2000 55:116-134.
[6]Krouse, JH, Krouse, HJ. Patient use of traditional and complementary therapies in treating rhinosinusitis before consulting an otolaryngologist [J]. Laryngoscope,1999,109:1223-1227.
[7]吴振华,陈协云.王行宽教授从肝论治过敏性鼻炎经验[J].光明中医,2010,25(9)：1575.
[7]Leynaert B, Neukirch C, Liard R,et al. Quality of life in allergic rhinitis and asthma. A population-based study of young adults. Am J Respir Crit Care Med.2000; 162:1391-1396.
[8]Bousquet J, Bullinger M,Fayol C,et al. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire.J Allergy Clin Immunol,1994,94:182-188
[10]王向东,张罗,赵岩.成人持续性变应性鼻炎生活质量评价和相关性分析,[J]中国耳鼻咽喉头颈外科,2007,14(11)：667-669.
[11]谭程,王燕萍,王朋等.从情志变化试论过敏性鼻炎的针灸取穴思路[J].广州中医药大学学报,2011,28(3)：319
[17]王向东,张罗,赵岩等.成人持续性变应性鼻炎生活质量评价和相关性分析[J].中国耳鼻咽喉头颈外科,2007,11：667-669.
[13]Roberts J,Huissoon A,Dretzke J,et al. A systematic review of the clinical effectiveness of acupuncture for allergic rhinitis.BMC Complement Altern Med, 2008:8-13.
[2]倪爱民.针刺治疗过敏性鼻炎与药物治疗对比观察[J].上海针灸杂志,2006,25(11)：16-17
[3]刘彩梅.针刺蝶腭神经节治疗鼻渊76例[J].现代中医药,2009,29；No.17006：51.
[4]王凤玲,许振林.针刺配合颧骼穴位注射治疗过敏性鼻炎疗效观察[J].职业与健康,2009,2517：1889-1890.
[5]王胜.深刺下关穴为主治疗过敏性鼻炎[J].针灸临床杂志,2010,2604：45-46.
[6]刘业帅,陈戈. “鼻三针”结合超短波治疗过敏性鼻炎的疗效观察[J].甘肃中医,2010,2308：31-32.
[7]桑莉.针刺治疗过敏性鼻炎45例分析[J].慢性病学杂志,2010,1201：58.
[8]陈仲新.针刺治疗过敏性鼻炎疗效观察[J].中国针灸,2007,27(8)：578-580.
[9]姚学英.针刺加艾灸治疗过敏性鼻炎60例[J].上海针灸杂志,2007,26(2)：14
[10]程艳红.头部电针透穴疗法治疗过敏性鼻炎45例[J].首都医药,2010,17(22)：45.
[11]李兰,白杨,陈新.针刺治疗过敏性鼻炎临床研究[J].辽宁中医杂志,2009,36(9)：1565-1566
[12]赵树波,宁金梅,刘德华,杨明早.针刺联合依巴斯汀治疗过敏性鼻炎的疗效观察[J].航空航天医学杂志,2012,23(10)：1248-1249.
[13]何天有,李惠琴,赵耀东.透刺为主治疗过敏性鼻炎60例[J].中国针灸,2006,26(2)：110-112.
[14]杨白燕.针刺治疗过敏性鼻炎62例临床观察[J].天津中医药,2008,25(1)：74.
[15]郑永生.针刺治疗花粉病[J].中国中医药现代远程教育,2011,9(3)：57.
[16]林艳霞,范丽英.针灸治疗急性发作期过敏性鼻炎的临床观察[J].海南医学院学报,2011,17(4)：508-510.
[17]罗雪梅,王建中.针刺穴位治疗过敏性鼻炎的疗效分析[J].中国临床医学,2012,(05)：553-554.
[18]王军,陈晟,谭程,赵吉平.灸法治疗常见过敏性疾病作用机制及临床应用探讨[J].临床误诊误治,2012,(03)：105-108.
[19]夏筱方.针刺加灸治疗过敏性鼻炎56例[J].甘肃中医,2006,11：35.
[20]陈振虎,江钢辉,王培源.针刺结合艾灸治疗过敏性鼻炎42例[J].四川中医,2005,09：102-103.
[21]胡志平,李小军,黄克伟,等.隔附子饼灸治疗过敏性鼻炎82例[J].上海针灸杂志,2005,22(5)：61.
[22]廉南,赵岚,雷中杰.针刺结合脐灸法治疗儿童过敏性鼻炎临床观察.成都中医药大学学报,20002,25(4)：12-13.
[23]张舒雁,杨金发,马泽云,等.三伏天穴位贴敷加卡介苗穴位注射防治变应性鼻炎50例观察[J].浙江中医杂志,2006,41(8)：475.
[24]姬晓兰,宋晓平.单用斑蝥天灸治疗过敏性鼻炎的临床研究.新疆中医药,2006,24(4)：42-44.
[25]李国徽,胡雨华,陈凌,等.三伏天灸治疗变应性鼻炎600例[J].陕西中医,20009,30(7)：885.
[26]王权全,陈海林,黄慧敏,等.穴位注射结合推拿治疗常年性过敏性鼻炎临床研究[J].中医学报,2012,27(2)：247.
[27]杨洋,吴乃桐.穴位注射配合自拟补肾脱敏汤治疗过敏性鼻炎71例[J].云南中医中药杂志,2010,31(5)：56.
[28]于力,高启孝.穴位注射治疗过敏性鼻炎的疗效观察.宁夏医学杂志,2006,28(4)：307-308.
[29]贺守阳.穴位埋线治疗过敏性鼻炎50例.针灸临床杂志,1997,13(Z1)：60-61.
[30]杜艳,吴海标,何邦广,等.背俞穴埋线治疗变应性鼻炎64例临床观察[J].河南中医,2009,29(4)：391.
[31]Er W,von Mutius E. Hygiene hypothesis and cndotoxin:what is the evidence?. Curr Opin Allergy Clin Immunol,2004,4 (2):113-117.
[32]Kim JI, Lee MS, Jung SY, et al. Acupuncture for persistent allergic rhinitis: a multi-centre, randomised, controlled trial protocol. Trials,2009 (10):54.
[33]Jan L, Bousquet J,Carlos E, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines:2010 Revision. J Allergy Clin Immunol,2010,126(3):466-476.
[34]Roberts J,Huissoon A, Dretzke J,et al.A systematic review of the clinical effectiveness of acupuncture for allergic rhinitis. BMC Complement Altcrn Med, 2008:8-13.
[35]Lee MS, Pittler MH, Shin BC,et al. Acupuncture for allergic rhinitis:a systematic review. Ann Allergy Asthma Immunol,2009(102):269-279.
[36]刘慧林,刘雪梅,史宗道.针刺临床对照试验中干预措施报告的标准：STRICTA(建议).中国循证医学杂志,2003,3(3)：235-237.
[37]费宇彤,刘建平.针刺临床试验中有关治疗措施的报告-STRICTA标准介绍及评价.中医杂志,2007,48(11)：983-985.
[38]Roberts, J., Huissoon, A., Dretzke, J.,Wang, D., Hyde, C.,2008. A systematic review of theclinical effectiveness of acupuncture for allergic rhinitis. BMC Complement. Altern. Med.8-13.
[39]Williamson, L., Yudkin, P., Livingston, R., Prasad, K., Fuller, A., Lawrence, M.,1996. Hay fever treatment in general practice:a randomised controlled trial comparing standardised western acupuncture with sham acupuncture. Acupunct. Med.14,6-10.
[40]Magnusson, A. L., Svcnsson, R. E., Leirvik, C., Gunnarsson, R. K.,2004. The effect ofacupuncturc on allergic rhinitis:a randomized controlled clinical trial. Am. J. Chin. Med.32,105-115.
[41]Xue, C.C., English, R., Zhang, J. J., Da Costa, C., Li, G.,2002. Effect of acupuncture in the treatment of seasonal allergic rhinitis:a randomized controlled clinical trial. Am. J.Chin. Med.30,1-11.
[42]Ng, D. K., Chow, P. Y., Ming, S. P., Hong, S. H., Lau, S., Tse, D., Kwong, W. K., Wong, M. F.,Wong, W. H., Fu, Y. M., Kwok, K. L., Li, H., Ho, J. C.,2004. A double- blind, randomized, placebo-controlled trial of acupuncture for the treatment of childhood persistent allergic rhinitis. Pediatrics 114,1242-1247.
[43]Wolkenstein E, Horak E. Protective effect of acupuncture in confrontation with rhinitis caused by allergen provocation. Wien Med Wschr.1998; 148:450-453.
[44]谭程,王朋,王军,王鹏,白鹏,张佳佳,石志红,赵吉平.过敏性鼻炎的针灸辨证论治思路[J].临床误诊误治,2012,(03)：102-105.
[1]Dykewicz MS, Fineman S, Skoner DP. Joint task force summary statements on diagnosis and management of rhinitis. Ann Allergy Asthma Immunol,1998;81 1240 (5 pt 2):474-7.
[2]international consensus report on diagnosis, management of rhinitis. International Rhinitis Management Working Group. Allergy 1994; 49 (suppl 19):1-34.
[3]Douglass JA, O'Hehir RE. Diagnosis, treatment and prevention of allergic disease:the basics. Med J Aust 2006;185 (4):228-33.
[4]Droste JH,Kerhof M,deMonchy JG,et al.Association of skin test reactivity, specific IgE, total IgE, and eosinophils with nasal symptoms in a community-based population study. The Dutch ECRHS Group. J Allergy Clin Immunol 1996; 97(4):922-32.
[5]Agency for Healthcare Research and Quality. Management of allergic and nonallergic rhinitis. Evidence report/technology assessment No.54, Publication No.1245 02-E024,May2002. Rockville, Md:Agency for Healthcare Research and Quality;
[6]Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811.
[7]Lambrecht BN. Allergen uptake and presentation by dendritic cells. Curr Opin Allergy Clin Immunol 2001; 1 (1):51-9.
[8]Takhar P, Smurthwaite L, Coker HA, et al. Allergen drives class switching to IgE in the nasal mucosa in allergic rhinitis. J Immunol 2005; 174(8):5024-32.
[9]Min YG. The pathophysiology, diagnosis and treatment of allergic rhinitis. Allergy Asthma Immunol Res 2010;2 (2):65-76.
[10]Willsie SK. Improved strategies and new treatment options for allergic rhinitis. J Am Osteopath Assoc 2002; 102(6 supplement 2):S7-S14.
[11]Brozek JL, Bousquet J, Baena-Cagnani CE,ct al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines:2010 revision. J Allergy Clin Immunol 2010; 126(3):466-76.
[12]Tashiro M, Sakurada Y, Iwabuchi K, ct al. Central effects of fexofenadine and cetirizine:measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. J Clin Pharmacol 2004;44 (8):890-900.
[13]Bousquet J, Van Cauwenberge P, Bachcrt C, ct al. Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI), Allergic Rhinitis and its Impact on Asthma (ARIA). Allergy 2003;58 (3):192-7.
[14]Bussc W, Kraft M. Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. Chest 2005;127 (4):1312-26.
[15]Modgill V, Badyal DK, Verghese A. Efficacy and safety of montelukast add-on therapy in allergic rhinitis. Methods Find Exp Clin Pharmacol 2010; 32(9):669-74
[16]Ramey JT, Bailen E, Lockey RF. Rhinitis medicamentosa. J Investig Allergol Clin Immunol 2006;16 (3):148-55.
[17]Stcnton GR, Chow SM, Lau HY. Inhibition of rat peritoncal mast cell exocytosis by frusemide:a comparison with disodium cromoglycatc. Life Sci 1998; 62 (3):PL49-54.
[18]Senti G, Prinz Vavricka BM, Erdmann I, et al.Intralymphatic allergen administration renders specific immunotherapy faster and safer:a randomized controlled trial. Proc Natl Acad Sci USA 2008;105 (46):8-12.
[19]Chervinsky P, Casale T, Townley R, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2003;91 (2):160-7.
[20]Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106 (2):253-9.
[21]Wright RJ, Cohen RT, Cohen S.The impact of stress on the development and expression of atopy. Curr Opin Allergy Clin Immunol 2005;5 (1):23-9.
[22]Postolache TT, Lapidus M, Sander ER, et al. Changes in allergy symptoms and depression scores are positively correlated in patients with recurrent mood disorders exposed to seasonal peaks in aeroaller-gens. Scientific World Journal 2008;7:1968-77
[23]Timonen M, Jokelainen J, Hakko H, et al. Atopy and depression:results from the Northern Finland 1966 Birth Cohort Study. Mol Psychiatry 2003; 8 (8):738-44.
[24]Postolache TT, Komarow H, Tonelli LH. Allergy:a risk factor for suicide? Curr Treat Options Neurol 2008;10(5):363-76.
[25]Marshall PS,O'Hara C, Steinberg P. Effects of seasonal allergic rhinitis on fatigue levels and mood. Psychosom Med 2002;64 (4):684-91.
[26]Tonelli LH, Stiller J, Rujescu D,et al. Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. Acta Psychiatr Scand 2008; 117(3):198-206.
[27]Mossner R, Daniel S, Schmitt A, et al. Modulation of serotonin transporter function by interleukin-4. Life Sci 2001;68 (8):873-80.
[1]中华耳鼻咽喉头颈外科杂志编辑委员会,中华医学会耳鼻咽喉科分会.变应性鼻炎诊断原则和推荐方案(2004,兰州).中华耳鼻咽喉科杂志,2005,166-167.
[2]Bousquet J, Khal taev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA (2)LEN and AllerGen). Allergy 2008;63 (suppl 86):8-160.
[3]Durham SR. Allergic rhinitis. In:Warrell DA, Cox TM, Firth JD, Benz EJJ, eds. Oxford Textbook of Medicine. Oxford, England:Oxford University Press; 2003:1325-1329.
[4]Gupta R, Sheikh A, Strachan DP, Anderson HR:Time trends in allergic disorders in the UK [J]. Thorax,2007,2:91-96.
[5]Van Cauwenberge P, Bachert C, Passalacqua, G, et al, Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology Allergy [J],2000 55:116-134.
[6]Krouse, JH, Krouse, HJ. Patient use of traditional and complementary therapies in treating rhinosinusitis before consulting an otolaryngologist [J]. Laryngoscope,1999,109:1223-1227.
[7]吴振华,陈协云.王行宽教授从肝论治过敏性鼻炎经验[J].光明中医,2010,25(9)：1575.
[7]Leynaert B, Neukirch C, Liard R,et al. Quality of life in allergic rhinitis and asthma. A population-based study of young adults. Am J Respir Crit Care Med.2000; 162:1391-1396.
[8]Bousquet J, Bullinger M,Fayol C,et al. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire.J Allergy Clin Immunol,1994,94:182-188
[10]王向东,张罗,赵岩.成人持续性变应性鼻炎生活质量评价和相关性分析,[J]中国耳鼻咽喉头颈外科,2007,14(11)：667-669.
[11]谭程,王燕萍,王朋等.从情志变化试论过敏性鼻炎的针灸取穴思路[J].广州中医药大学学报,2011,28(3)：319
[17]王向东,张罗,赵岩等.成人持续性变应性鼻炎生活质量评价和相关性分析[J].中国耳鼻咽喉头颈外科,2007,11：667-669.
[13]Roberts J,Huissoon A,Dretzke J,et al. A systematic review of the clinical effectiveness of acupuncture for allergic rhinitis.BMC Complement Altern Med, 2008:8-13.